A systematic review of the cost-effectiveness of renal replacement therapies, and consequences for decision-making in the end-stage renal disease treatment pathway
Open Access
- 18 June 2022
- journal article
- review article
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 24 (3) , 377-392
Abstract
Objectives: Comparative economic assessments of renal replacement therapies (RRT) are common and often used to inform national policy in the management of end-stage renal disease (ESRD). This study aimed to assess existing cost-effectiveness analyses of dialysis modalities and consider whether the methods applied and results obtained reflect the complexities of the real-world treatment pathway experienced by ESRD patients. Methods: A systematic literature review (SLR) was conducted to identify cost-effectiveness studies of dialysis modalities from 2005 onward by searching Embase, MEDLINE, EBM reviews, and EconLit. Economic evaluations were included if they compared distinct dialysis modalities (e.g. in-centre haemodialysis [ICHD], home haemodialysis [HHD] and peritoneal dialysis [PD]). Results: In total, 19 cost-effectiveness studies were identified. There was considerable heterogeneity in perspectives, time horizon, discounting, utility values, sources of clinical and economic data, and extent of clinical and economic elements included. The vast majority of studies included an incident dialysis patient population. All studies concluded that home dialysis treatment options were cost-effective interventions. Conclusions: Despite similar findings across studies, there are a number of uncertainties about which dialysis modalities represent the most cost-effective options for patients at different points in the care pathway. Most studies included an incident patient cohort; however, in clinical practice, patients may switch between different treatment modalities over time according to their clinical need and personal circumstances. Promoting health policies through financial incentives in renal care should reflect the cost-effectiveness of a comprehensive approach that considers different RRTs along the patient pathway; however, no such evidence is currently available.Keywords
Funding Information
- Fresenius Medical Care
This publication has 42 references indexed in Scilit:
- The natural history of, and risk factors for, progressive Chronic Kidney Disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocolBMC Nephrology, 2013
- Cost-Effectiveness Analysis of the Spanish Renal Replacement Therapy ProgramPeritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2012
- Cost-effectiveness analysis of renal replacement therapy in AustriaNephrology Dialysis Transplantation, 2011
- Educating end-stage renal disease patients on dialysis modality selection: clinical advice from the European Renal Best Practice (ERBP) Advisory BoardNephrology Dialysis Transplantation, 2010
- The cost‐effectiveness of increasing kidney transplantation and home‐based dialysisNephrology, 2009
- Monitoring of the peritoneal membraneClinical Kidney Journal, 2008
- An estimate of lifelong costs and QALYs in renal replacement therapy based on patients’ life expectancyHealth Policy, 2008
- Reimbursement and economic factors influencing dialysis modality choice around the worldNephrology Dialysis Transplantation, 2008
- Economic Evaluation of Palliative Management versus Peritoneal Dialysis and Hemodialysis for End-Stage Renal Disease: Evidence for Coverage Decisions in ThailandValue in Health, 2007
- Guidelines for authors and peer reviewers of economic submissions to the BMJBMJ, 1996